{
    "root": "cc805aea-2daa-4855-8c1d-7233738b6e6f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Hepzato Kit",
    "value": "20250519",
    "ingredients": [],
    "indications": "hepzato injection , component hepzato kit , indicated liver-directed treatment adult patients uveal melanoma unresectable hepatic metastases affecting less 50 % liver extrahepatic disease extrahepatic disease limited bone , lymph nodes , subcutaneous tissues , lung amenable resection radiation .",
    "contraindications": "hepzato , component hepzato kit , administered intra-arterial infusion hepatic artery ( instructions [ ifu ] ) . recommended dose 3 mg/kg based ideal body weight ( table 1 ) , maximum absolute dose 220 mg single hepzato treatment . ( 2.2 ) . infused 30 minutes followed 30-minute washout period ( ifu ) . treatments administered every six ( 6 ) eight ( 8 ) weeks delayed recovery toxicities per judgement . ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "hepzato hepzato kit contraindicated patients : active intracranial metastases brain lesions propensity bleed liver failure , portal hypertension , known varices risk bleeding surgery medical treatment liver previous 4 weeks uncorrectable coagulopathy inability safely undergo general anesthesia , including active cardiac conditions including , limited , unstable coronary syndromes ( unstable severe angina myocardial infarction ) , worsening new-onset congestive heart failure , significant arrhythmias , severe valvular disease history allergies known hypersensitivity melphalan history allergies known hypersensitivity component material utilized within hepzato kit including history allergy natural rubber latex history allergy hypersensitivity heparin presence heparin-induced thrombocytopenia ( hit ) history severe allergic reaction iodinated contrast controlled premedication antihistamines steroids",
    "indications_original": "HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.",
    "contraindications_original": "HEPZATO, a component of the HEPZATO KIT, is administered by intra-arterial infusion into the hepatic artery (see instructions for use [IFU]). The recommended dose is 3 mg/kg based on ideal body weight (see Table 1 ), with a maximum absolute dose of 220Â mg during a single HEPZATO treatment. ( 2.2 ). The drug is infused over 30 minutes followed by a 30-minute washout period (see IFU). Treatments should be administered every six (6) to eight (8) weeks but can be delayed until recovery from toxicities and as per clinical judgement. ( 2.3 )",
    "adverseReactions_original": "HEPZATO and the HEPZATO KIT are contraindicated in patients with:\n\n                  \n                     Active intracranial metastases or brain lesions with a propensity to bleed\n\n                     Liver failure, portal hypertension, or known varices at risk for bleeding\n\n                     Surgery or medical treatment of the liver in the previous 4 weeks\n\n                     Uncorrectable coagulopathy\n\n                     Inability to safely undergo general anesthesia, including active cardiac conditions including, but not limited to, unstable coronary syndromes (unstable or severe angina or myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias, or severe valvular disease\n\n                     History of allergies or known hypersensitivity to melphalan\n\n                     History of allergies or known hypersensitivity to a component or material utilized within the HEPZATO KIT including\n                           History of allergy to natural rubber latex\n\n                           History of allergy or hypersensitivity to heparin or presence of heparin-induced thrombocytopenia (HIT)\n\n                           History of severe allergic reaction to iodinated contrast not controlled by premedication with antihistamines and steroids"
}